“Rising Adoption of Immunotherapy in Vulvar Cancer Treatment”
One significant trend driving the growth of the vulvar cancer market is the rising adoption of immunotherapy. Immunotherapy treatments, such as immune checkpoint inhibitors, are becoming increasingly important in treating advanced vulvar cancer. These therapies work by enhancing the body’s immune system to fight cancer cells. For instance, pembrolizumab (Keytruda) has shown promising results in clinical trials, demonstrating its potential to improve survival rates. With immunotherapy offering a new treatment option for patients with limited alternatives, the market is witnessing growth in demand for these innovative treatments. The growing approval of immunotherapies by regulatory authorities is further fueling the market's expansion.
